focus -WSS

focus

author：hotspot 2025-08-12 08:25:55 - browse：8961

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Eli Lilly, Pfizer, and others want in on the online prescription market

focus

hotspot

WSS

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Kim Kardashian sparks debate on benefits of full

CDC overhauls leadership of center that led response to Covid

Eli Lilly, Pfizer, and others want in on the online prescription market

Pharma budget tightening trickles down to Doximity

Independent physicians launch a new lobbying group

explore

focus

focus

Hollywood unions extend contract negotiations for actors

Covid's long

Hepatitis C has a cure — but many Americans still lack access to it

New brain studies show LSD's effects on the brain in full color

Anesthesiologist group: stop taking Ozempic before surgery

Maui funeral service workers on devastation of fires: 'I'm in shock'

Medicare proposal to cover medical devices draws a mixed reaction

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

After affirmative action ruling, medical educators look to 'holistic review'

Why doctors need education on FDA device approval process

hotspot

EU regulator recommends expanding Mounjaro approval to obesity

Faced with fears of OxyContin misuse, sales reps touted its safety

Biotech venture capitalists face new demands from investors

Humana cuts profit projections as Medicare Advantage costs soar

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Elizabeth Holmes banned from government health programs

focus

hotspot

hotspot

leisure time